During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for ...

Nuvation Bio, listed via SPAC in 2021, and acquired AnHeart Therapeutics last year, gaining taletrectinib, a promising ROS1 inhibitor indicated for non-small cell lung cancer. The FDA has accepted ...

“This EAP reflects our unwavering dedication to patients with ROS1-positive NSCLC,” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. “We are committed ...

ROS1 is a rare mutation found in fewer than 2% of NSCLC cases. Currently there is a lack of treatments for ROS1-positive NSCLC, especially for people whose lung cancer has spread to the brain.

Nuvation Bio (NYSE:NUVB) said the FDA has accepted its application with priority review for its therapy taletrectinib in the treatment of advanced ROS1+ non-small cell lung cancer.

The program targets individuals with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have exhausted other treatment options. The EAP, authorized by the U.S ...

On the 5th, HLB PANAGENE said that the "PANAMutyper™ ROS1" has received item approval from the Ministry of Food and Drug Safety as a companion diagnostic product for Pfizer's lung cancer ...

As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...

Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial results for the fourth quarter and full year ended ...